Cargando…

Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs

Background. Low-risk prostate cancer patients enrolled in active surveillance programs commonly undergo biopsies for examination of cancer progression. Biopsies are conducted as per a fixed and frequent schedule (e.g., annual biopsies). Since biopsies are burdensome, patients do not always comply wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomer, Anirudh, Rizopoulos, Dimitris, Nieboer, Daan, Drost, Frank-Jan, Roobol, Monique J., Steyerberg, Ewout W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791024/ https://www.ncbi.nlm.nih.gov/pubmed/31319751 http://dx.doi.org/10.1177/0272989X19861963

Ejemplares similares

Shared decision making of burdensome surveillance tests using personalized schedules and their burden and benefit
por: Tomer, Anirudh, et al.
Publicado: (2022)

Personalized schedules for surveillance of low‐risk prostate cancer patients
por: Tomer, Anirudh, et al.
Publicado: (2018)

Personalised biopsy schedules based on risk of Gleason upgrading for patients with low‐risk prostate cancer on active surveillance
por: Tomer, Anirudh, et al.
Publicado: (2020)

Active surveillance: a review of risk-based, dynamic monitoring
por: Nieboer, Daan, et al.
Publicado: (2018)

A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy
por: Verbeek, Jan F.M., et al.
Publicado: (2019)

Comparison of biopsy under‐sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies
por: Li, Weiyu, et al.
Publicado: (2020)

Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome
por: Pereira-Azevedo, Nuno, et al.
Publicado: (2018)

Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer
por: Venderbos, Lionne D. F., et al.
Publicado: (2015)

The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam
por: Remmers, Sebastiaan, et al.
Publicado: (2023)

Improving prediction models with new markers: a comparison of updating strategies
por: Nieboer, D., et al.
Publicado: (2016)

A personalized and dynamic risk estimation model: The new paradigm in Barrett’s esophagus surveillance
por: Roumans, Carlijn A. M., et al.
Publicado: (2022)

Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies
por: van Leeuwen, Pim J., et al.
Publicado: (2016)

Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
por: Osses, Daniël F., et al.
Publicado: (2020)

Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database
por: Beckmann, Kerri R., et al.
Publicado: (2022)

Personalized Decision Making on Genomic Testing in Early Breast Cancer: Expanding the MINDACT Trial with Decision-Analytic Modeling
por: Steyerberg, Ewout W., et al.
Publicado: (2021)

Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions
por: Schoots, Ivo G., et al.
Publicado: (2019)

Prostate cancer screening and active surveillance in the Western world
por: Roobol, Monique J.
Publicado: (2018)

Assessing Discriminative Performance at External Validation of Clinical Prediction Models
por: Nieboer, Daan, et al.
Publicado: (2016)

Predicting biochemical recurrence and prostate cancer‐specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening‐ and clinically detected prostate cancer
por: Remmers, Sebastiaan, et al.
Publicado: (2019)

Active surveillance for prostate cancer—will the discoveries of the last 5 years change the future?
por: Roobol, Monique J.
Publicado: (2021)

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
por: Schoots, Ivo G., et al.
Publicado: (2018)

Personalized strategies in population screening for prostate cancer
por: Remmers, Sebastiaan, et al.
Publicado: (2020)

Screening for prostate cancer: are organized screening programs necessary?
por: Roobol, Monique J.
Publicado: (2018)

Personalized screening intervals for kidney function in patients with chronic heart failure: a modeling study
por: Schuurman, Anne-Sophie, et al.
Publicado: (2021)

Comparison of clinically significant prostate cancer detection by MRI cognitive biopsy and in-bore MRI-targeted biopsy for naïve biopsy patients
por: Zhang, Kai, et al.
Publicado: (2020)

Active surveillance for prostate cancer
por: Shill, Daniela K., et al.
Publicado: (2021)

Assessment of heterogeneity in an individual participant data meta‐analysis of prediction models: An overview and illustration
por: Steyerberg, Ewout W., et al.
Publicado: (2019)

Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification
por: Davik, Petter, et al.
Publicado: (2022)

Active Surveillance for Prostate Cancer: Past, Current, and Future Trends
por: de Vos, Ivo I., et al.
Publicado: (2023)

Performance of IMPACT, CRASH and Nijmegen models in predicting six month outcome of patients with severe or moderate TBI: an external validation study
por: Majdan, Marek, et al.
Publicado: (2014)

Using the Movember Foundation’s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function—a retrospective study in low-risk prostate cancer patients
por: Crump, R. Trafford, et al.
Publicado: (2021)

The Accuracy of Transrectal Ultrasound-Guided Biopsy for Decision Making in Prostate Cancer
por: Ghadian, Ali Reza, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy
por: Huang, Da, et al.
Publicado: (2020)

Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
por: Mandel, Philipp, et al.
Publicado: (2021)

A personalized decision aid for prostate cancer shared decision making
por: Bagshaw, Hilary P., et al.
Publicado: (2021)

Validation of prediction models: examining temporal and geographic stability of baseline risk and estimated covariate effects
por: Austin, Peter C., et al.
Publicado: (2017)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
por: Olivier, Jonathan, et al.
Publicado: (2022)

Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study
por: Drost, Frank-Jan H., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_av3tncg6iitm43dii4l9unibl6